Benzinga · Feb 4, 2026
NASDAQ · AYTU
Aytu BioPharma, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$2.05
Up+$0.00 (+0.00%)
Updated Oct 9, 2026, 4:02 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 16.53M
- P/E ratio
- -1.68
- Dividend yield
- 0.00%
- 52-week range
- $1.80 – $3.07
- Volume
- 5.63K
- Avg. volume
- 176.83K
Price performance · AYTU
AYTU price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
AYTU closed at $2.05 after 21 trading sessions, up 0.00% for the selected period.
- Last close
- $2.05
- Period change
- +0.00%
- Period low
- $1.97
- Period high
- $2.31
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $2.05 | $2.09 | $2.045 | $2.05 | 5.63K |
| Oct 7, 2026 | $2.04 | $2.095 | $2.03 | $2.05 | 5.73K |
| Oct 6, 2026 | $2.05 | $2.09 | $2.02 | $2.05 | 21.63K |
| Oct 5, 2026 | $2.05 | $2.15 | $2.04 | $2.04 | 63.92K |
| Oct 2, 2026 | $2.08 | $2.15 | $2.06 | $2.07 | 15.8K |
| Oct 1, 2026 | $2.15 | $2.15 | $2.04 | $2.09 | 29.93K |
| Sep 30, 2026 | $2.18 | $2.20 | $2.13 | $2.14 | 67.73K |
| Sep 29, 2026 | $2.19 | $2.2004 | $2.15 | $2.20 | 37.07K |
| Sep 28, 2026 | $2.23 | $2.242 | $2.17 | $2.17 | 16.84K |
| Sep 25, 2026 | $2.28 | $2.29 | $2.21 | $2.28 | 28.18K |
| Sep 24, 2026 | $2.23 | $2.34 | $2.21 | $2.31 | 69.99K |
| Sep 23, 2026 | $2.34 | $2.35 | $2.121 | $2.28 | 187.89K |
| Sep 22, 2026 | $2.18 | $2.33 | $2.14 | $2.23 | 277.75K |
| Sep 21, 2026 | $2.20 | $2.20 | $2.10 | $2.125 | 49.41K |
| Sep 18, 2026 | $2.00 | $2.17 | $2.00 | $2.12 | 54.95K |
| Sep 17, 2026 | $2.1497 | $2.1497 | $1.97 | $2.00 | 7.1K |
| Sep 16, 2026 | $1.89 | $2.01 | $1.89 | $1.97 | 17.02K |
| Sep 15, 2026 | $2.00 | $2.0699 | $1.975 | $1.99 | 37.62K |
| Sep 14, 2026 | $2.0939 | $2.0999 | $1.95 | $2.00 | 28.54K |
| Sep 11, 2026 | $2.08 | $2.08 | $1.99 | $1.99 | 61.57K |
| Sep 10, 2026 | $2.15 | $2.15 | $2.05 | $2.05 | 28.78K |
Latest AYTU news
The latest Smart Investors Daily articles mentioning AYTU.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AYTU research
Overview
Company profile and research snapshot.
Company profile
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | Ascendiant Capital | Buy | — |
| Jun 11, 2026 | Ascendiant Capital | Buy | — |
| Dec 10, 2025 | Ascendiant Capital | Buy | — |
| Sep 25, 2025 | Ascendiant Capital | Buy | — |
| Sep 25, 2025 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 3, 2026
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Yahoo · Feb 2, 2026
New Strong Sell Stocks for February 2nd
AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.
Yahoo · Jan 27, 2026
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of ...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
